Hemostatic efficacy and anti-FXa (factor Xa) reversal with andexanet alfa in intracranial hemorrhage: ANNEXA-4 substudy
AM Demchuk, P Yue, E Zotova, J Nakamya, L Xu… - Stroke, 2021 - Am Heart Assoc
Background and Purpose: Andexanet alfa is a recombinant modified human FXa (factor Xa)
developed to reverse FXa inhibition from anticoagulants. Hemostatic efficacy and reversal of …
developed to reverse FXa inhibition from anticoagulants. Hemostatic efficacy and reversal of …
Final study report of andexanet alfa for major bleeding with factor Xa inhibitors
TJ Milling Jr, S Middeldorp, L Xu, B Koch, A Demchuk… - Circulation, 2023 - Am Heart Assoc
Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …
An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage
A Giovino, E Shomo, KV Busey, D Case… - Clinical Neurology and …, 2020 - Elsevier
Objective Intracranial hemorrhage is a life threatening complication of factor Xa inhibitors.
Except for results of the open-label, single-arm ANNEXA-4 study, published real-world …
Except for results of the open-label, single-arm ANNEXA-4 study, published real-world …
[HTML][HTML] Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
Introduction A reversal agent for factor Xa (FXa) inhibitors, andexanet alfa, was Food and
Drug Administration approved without extensive study of clinical effectiveness, due to an …
Drug Administration approved without extensive study of clinical effectiveness, due to an …
Retrospective comparison of andexanet alfa and 4-factor prothrombin complex for reversal of factor Xa-inhibitor related bleeding
VM Stevens, TC Trujillo, TH Kiser… - Clinical and Applied …, 2021 - journals.sagepub.com
The aim of this retrospective study was to compare andexanet alfa and 4-factor prothrombin
complex (4F-PCC) for reversal of factor Xa (FXa)-inhibitor bleeding. Patients that received …
complex (4F-PCC) for reversal of factor Xa (FXa)-inhibitor bleeding. Patients that received …
Hematoma expansion and clinical outcomes in patients with factor-Xa inhibitor–related atraumatic intracerebral hemorrhage treated within the ANNEXA-4 trial versus …
HB Huttner, ST Gerner, JB Kuramatsu, SJ Connolly… - Stroke, 2022 - Am Heart Assoc
Background and Purpose: It is unestablished whether andexanet alfa, compared with
guideline-based usual care including prothrombin complex concentrates, is associated with …
guideline-based usual care including prothrombin complex concentrates, is associated with …
Andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitors in intracranial hemorrhage
Abstract Background/Objective There are limited data on the risks and benefits of using
andexanet alfa (AA) in comparison with four-factor prothrombin complex concentrate (4F …
andexanet alfa (AA) in comparison with four-factor prothrombin complex concentrate (4F …
Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage
SJ Connolly, M Sharma, AT Cohen… - … England Journal of …, 2024 - Mass Medical Soc
Background Patients with acute intracerebral hemorrhage who are receiving factor Xa
inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that …
inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that …
Economic evaluation of andexanet versus prothrombin complex concentrate for reversal of factor Xa-associated intracranial hemorrhage
A Micieli, AM Demchuk, HC Wijeysundera - Stroke, 2021 - Am Heart Assoc
Background and Purpose: Andexanet was approved by the Food and Drug Administration in
2018 for reversal of life-threatening or uncontrolled bleeding associated with factor Xa …
2018 for reversal of life-threatening or uncontrolled bleeding associated with factor Xa …
Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors
Background Andexanet alfa is a modified recombinant inactive form of human factor Xa
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had …
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had …